---
document_datetime: 2025-12-29 11:01:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ponvory.html
document_name: ponvory.html
version: success
processing_time: 0.1113163
conversion_datetime: 2025-12-29 23:05:23.981231
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ponvory

[RSS](/en/individual-human-medicine.xml/67445)

##### Authorised

This medicine is authorised for use in the European Union

ponesimod Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ponvory](#news-on)
- [More information on Ponvory](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ponvory is a medicine for treating adults with relapsing active forms of multiple sclerosis.

Multiple sclerosis is a disease of the brain and spinal cord in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.

Ponvory contains the active substance ponesimod.

Expand section

Collapse section

## How is Ponvory used?

Ponvory is available as tablets. For the first two weeks, the patient takes tablets once daily with the dose increasing from 2 mg to 10 mg. After two weeks the patient takes a single 20 mg tablet once a day.

The medicine can only be obtained with a prescription. Treatment is started under the supervision of a doctor experienced in managing multiple sclerosis. For more information, including about the dosing, see the package leaflet or contact your doctor or pharmacist.

## How does Ponvory work?

In multiple sclerosis, the immune system (the body's natural defences) incorrectly attacks the protective sheath around the nerves and the nerves themselves in the brain and spinal cord.

The active substance in Ponvory, ponesimod, blocks T cells and B cells (two types of white blood cells involved in the immune system) inside the lymph nodes. Ponesimod does this by binding to a target (receptor), called the sphingosine-1-phosphate receptor, on the surface of T cells and B cells, which the cells need to leave the lymph nodes. By blocking these cells in the lymph nodes, Ponvory prevents them from traveling towards the brain and spinal cord, thus limiting the damage they cause in patients with multiple sclerosis.

## What benefits of Ponvory have been shown in studies?

A main study involving 1,133 adults with relapsing forms of multiple sclerosis showed that Ponvory was more effective than another multiple sclerosis medicine, teriflunomide, at reducing the number of relapses (flare-ups). After two years of treatment, the average number of relapses a year in patients taking Ponvory was 0.2 compared with 0.3 in patients taking teriflunomide. The average number of relapses in a year was reduced by about a third in patients taking Ponvory compared with patients taking teriflunomide.

## What are the risks associated with Ponvory?

The most common side effects of Ponvory (which may affect more than 1 in 10 people) are infections of the nose and throat and increased levels of liver enzymes. For the full list of side effects of Ponvory, see the package leaflet.

Ponvory must not be used in patients who have recently experienced certain heart problems or stroke and in patients with problems with heart rhythm, severely weakened immune system, severe or long-term infections, cancer, or moderate or severe liver problems. It must also not be taken during pregnancy or by women who can have children and are not using effective contraception. For the full list of restrictions, see the package leaflet.

## Why is Ponvory authorised in the EU?

A main study showed that Ponvory was more effective than teriflunomide at reducing the number of relapses in patients with relapsing forms of multiple sclerosis. The side effects that occur with Ponvory are similar to those seen with medicines of the same class and are considered manageable.

The European Medicines Agency therefore decided that Ponvory's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ponvory?

The company that markets Ponvory must distribute educational material for healthcare professionals and patients with information on the use of the medicine, such as dosing, monitoring and tests to be carried out before treatment. The company will also provide information about avoiding pregnancy while taking Ponvory.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ponvory have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ponvory are continuously monitored. Side effects reported with Ponvory are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ponvory

Ponvory received a marketing authorisation valid throughout the EU on 19 May 2021.

Ponvory : EPAR - Medicine overview

Reference Number: EMA/251618/2021

English (EN) (99.04 KB - PDF)

**First published:** 02/06/2021

[View](/en/documents/overview/ponvory-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-380)

български (BG) (131.94 KB - PDF)

**First published:**

02/06/2021

[View](/bg/documents/overview/ponvory-epar-medicine-overview_bg.pdf)

español (ES) (109.4 KB - PDF)

**First published:**

02/06/2021

[View](/es/documents/overview/ponvory-epar-medicine-overview_es.pdf)

čeština (CS) (129.71 KB - PDF)

**First published:**

02/06/2021

[View](/cs/documents/overview/ponvory-epar-medicine-overview_cs.pdf)

dansk (DA) (108.36 KB - PDF)

**First published:**

02/06/2021

[View](/da/documents/overview/ponvory-epar-medicine-overview_da.pdf)

Deutsch (DE) (111.95 KB - PDF)

**First published:**

02/06/2021

[View](/de/documents/overview/ponvory-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.51 KB - PDF)

**First published:**

02/06/2021

[View](/et/documents/overview/ponvory-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.35 KB - PDF)

**First published:**

02/06/2021

[View](/el/documents/overview/ponvory-epar-medicine-overview_el.pdf)

français (FR) (110.95 KB - PDF)

**First published:**

02/06/2021

[View](/fr/documents/overview/ponvory-epar-medicine-overview_fr.pdf)

hrvatski (HR) (127.87 KB - PDF)

**First published:**

02/06/2021

[View](/hr/documents/overview/ponvory-epar-medicine-overview_hr.pdf)

italiano (IT) (107.46 KB - PDF)

**First published:**

02/06/2021

[View](/it/documents/overview/ponvory-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (135.96 KB - PDF)

**First published:**

02/06/2021

[View](/lv/documents/overview/ponvory-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (129.64 KB - PDF)

**First published:**

02/06/2021

[View](/lt/documents/overview/ponvory-epar-medicine-overview_lt.pdf)

magyar (HU) (130.63 KB - PDF)

**First published:**

02/06/2021

[View](/hu/documents/overview/ponvory-epar-medicine-overview_hu.pdf)

Malti (MT) (131.52 KB - PDF)

**First published:**

02/06/2021

[View](/mt/documents/overview/ponvory-epar-medicine-overview_mt.pdf)

Nederlands (NL) (108.09 KB - PDF)

**First published:**

02/06/2021

[View](/nl/documents/overview/ponvory-epar-medicine-overview_nl.pdf)

polski (PL) (133.33 KB - PDF)

**First published:**

02/06/2021

[View](/pl/documents/overview/ponvory-epar-medicine-overview_pl.pdf)

português (PT) (110.33 KB - PDF)

**First published:**

02/06/2021

[View](/pt/documents/overview/ponvory-epar-medicine-overview_pt.pdf)

română (RO) (127.8 KB - PDF)

**First published:**

02/06/2021

[View](/ro/documents/overview/ponvory-epar-medicine-overview_ro.pdf)

slovenčina (SK) (129.77 KB - PDF)

**First published:**

02/06/2021

[View](/sk/documents/overview/ponvory-epar-medicine-overview_sk.pdf)

slovenščina (SL) (127.66 KB - PDF)

**First published:**

02/06/2021

[View](/sl/documents/overview/ponvory-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.32 KB - PDF)

**First published:**

02/06/2021

[View](/fi/documents/overview/ponvory-epar-medicine-overview_fi.pdf)

svenska (SV) (108.31 KB - PDF)

**First published:**

02/06/2021

[View](/sv/documents/overview/ponvory-epar-medicine-overview_sv.pdf)

Ponvory : EPAR - Risk management plan

English (EN) (1.96 MB - PDF)

**First published:** 02/06/2021

**Last updated:** 15/10/2025

[View](/en/documents/rmp/ponvory-epar-risk-management-plan_en.pdf)

## Product information

Ponvory : EPAR - Product information

English (EN) (881.53 KB - PDF)

**First published:** 02/06/2021

**Last updated:** 23/10/2025

[View](/en/documents/product-information/ponvory-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-520)

български (BG) (740.56 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/bg/documents/product-information/ponvory-epar-product-information_bg.pdf)

español (ES) (724.25 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/es/documents/product-information/ponvory-epar-product-information_es.pdf)

čeština (CS) (727.19 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/cs/documents/product-information/ponvory-epar-product-information_cs.pdf)

dansk (DA) (716.11 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/da/documents/product-information/ponvory-epar-product-information_da.pdf)

Deutsch (DE) (754.17 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/de/documents/product-information/ponvory-epar-product-information_de.pdf)

eesti keel (ET) (714.21 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/et/documents/product-information/ponvory-epar-product-information_et.pdf)

ελληνικά (EL) (782.4 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/el/documents/product-information/ponvory-epar-product-information_el.pdf)

français (FR) (738.73 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/fr/documents/product-information/ponvory-epar-product-information_fr.pdf)

hrvatski (HR) (716.38 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/hr/documents/product-information/ponvory-epar-product-information_hr.pdf)

íslenska (IS) (706.75 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/is/documents/product-information/ponvory-epar-product-information_is.pdf)

italiano (IT) (743.13 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/it/documents/product-information/ponvory-epar-product-information_it.pdf)

latviešu valoda (LV) (731.62 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/lv/documents/product-information/ponvory-epar-product-information_lv.pdf)

lietuvių kalba (LT) (737.52 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/lt/documents/product-information/ponvory-epar-product-information_lt.pdf)

magyar (HU) (738.75 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/hu/documents/product-information/ponvory-epar-product-information_hu.pdf)

Malti (MT) (863.89 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/mt/documents/product-information/ponvory-epar-product-information_mt.pdf)

Nederlands (NL) (733.02 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/nl/documents/product-information/ponvory-epar-product-information_nl.pdf)

norsk (NO) (692.77 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/no/documents/product-information/ponvory-epar-product-information_no.pdf)

polski (PL) (1.02 MB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/pl/documents/product-information/ponvory-epar-product-information_pl.pdf)

português (PT) (732.69 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/pt/documents/product-information/ponvory-epar-product-information_pt.pdf)

română (RO) (729.83 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/ro/documents/product-information/ponvory-epar-product-information_ro.pdf)

slovenčina (SK) (712.08 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/sk/documents/product-information/ponvory-epar-product-information_sk.pdf)

slovenščina (SL) (796.15 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/sl/documents/product-information/ponvory-epar-product-information_sl.pdf)

Suomi (FI) (714.15 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/fi/documents/product-information/ponvory-epar-product-information_fi.pdf)

svenska (SV) (702.35 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

23/10/2025

[View](/sv/documents/product-information/ponvory-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0018/G 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ponvory : EPAR - All authorised presentations

English (EN) (26.02 KB - PDF)

**First published:** 02/06/2021

**Last updated:** 15/03/2022

[View](/en/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-377)

български (BG) (28.06 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/bg/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.62 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/es/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_es.pdf)

čeština (CS) (26.79 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/cs/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.13 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/da/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.54 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/de/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.69 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/et/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (27.95 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/el/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_el.pdf)

français (FR) (26.11 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/fr/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.29 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/hr/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.11 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/is/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.54 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/it/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.68 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/lv/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.47 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/lt/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/hu/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.75 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/mt/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.14 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/nl/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (25.97 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/no/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.7 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/pl/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.73 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/pt/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_pt.pdf)

română (RO) (25.95 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/ro/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.74 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/sk/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.34 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/sl/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.1 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/fi/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.71 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

15/03/2022

[View](/sv/documents/all-authorised-presentations/ponvory-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ponvory Active substance ponesimod International non-proprietary name (INN) or common name ponesimod Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04AE04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

## Authorisation details

EMA product number EMEA/H/C/005163

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Laboratoires Juvisé Pharmaceuticals

149 Boulevard Bataille de Stalingrad 69100 Villeurbanne FRANCE

Opinion adopted 25/03/2021 Marketing authorisation issued 19/05/2021 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ponvory : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (269.16 KB - PDF)

**First published:** 05/02/2025

**Last updated:** 22/07/2025

[View](/en/documents/procedural-steps-after/ponvory-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ponvory : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (167.78 KB - PDF)

**First published:** 15/03/2022

**Last updated:** 15/10/2025

[View](/en/documents/procedural-steps-after/ponvory-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ponvory-H-C-PSUSA-00010940-202209 : EPAR - Scientific conclusions and grounds for the variation to the  terms of the marketing authorisation

Reference Number: EMA/173624/2023

English (EN) (126.4 KB - PDF)

**First published:** 13/07/2023

[View](/en/documents/scientific-conclusion/ponvory-h-c-psusa-00010940-202209-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ponvory : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/206970/2021

English (EN) (3.45 MB - PDF)

**First published:** 02/06/2021

[View](/en/documents/assessment-report/ponvory-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ponvory

Adopted

Reference Number: EMA/CHMP/164792/2021

English (EN) (96.44 KB - PDF)

**First published:** 26/01/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ponvory_en.pdf)

#### News on Ponvory

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021) 26/03/2021

#### More information on Ponvory

- [EMEA-000798-PIP01-09-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000798-pip01-09-m04)
- [Survey to Assess the Effectiveness of Ponvory® Educational Materials for Additional Risk Minimization Measures in the European Union - post-authorisation study](https://catalogues.ema.europa.eu/study/107764)

**This page was last updated on** 23/10/2025

## Share this page

[Back to top](#main-content)